The HemaCore Company, a resident of the Biomedical Cluster of Skolkovo Foundation – HemaCore Labs, was introduced to European investors and innovation market participants on the main stage of the Slush.
HemaCore was the only company from Russia that enjoyed the attention of the entire audience of the largest European start-up community conference, having presented its individual pitch “Is it possible to predict a cardiovascular catastrophe?” HemaCore is a developer and manufacturer of fundamentally new equipment for blood coagulation process diagnosis.
HemaCore Labs deserves the biggest European audience. It was our prime candidate on the Slush for big business access, says Ruslan Altayev, head of medical devices and diagnostics at the Skolkovo Foundation. “This case deserves more attention, the company is already on the market, and probably they will be the first resident of our cluster that will make sales in Europe, and therefore, it is very important for us to promote them among European audience,” adds Ruslan Altayev.
Igor Pivovarov, CEO of HemaCore, who had spoken in tandem with R. Altayev, remarked in his interview that his company was working in the area of personalized medicine, which was a relatively new, and one of the most promising global trends in healthcare. “Our method of blood coagulation diagnosis, allows anticipating adverse thrombosis effects, and choosing an individual treatment for each patient,” he said.